Abstract
Rationale
Long-acting antipsychotics such as haloperidol decanoate are becoming more commonly used. Long-acting depot formulations have several advantages, but secondary negative effects of prolonged delivery, including motivational dysfunctions, could have debilitating effects. Assessing the behavioral changes that emerge during chronic antipsychotic administration in rats could provide insight regarding the development of motivational dysfunctions and drug tolerance.
Objectives
Acute administration of dopamine D2 antagonists such as haloperidol induce motivational deficits in rats, as marked by a shift towards a low-effort bias during effort-based choice tasks. In the present studies, programmable subcutaneous infusion pumps provided continuous and controlled drug delivery of haloperidol. Animals were assessed using a fixed ratio (FR) 5 lever pressing schedule and the FR5/chow feeding test of effort-based choice. The adenosine A2A antagonist istradefylline was studied for its ability to reverse the effects of chronic haloperidol.
Results
Continuous chronic infusions of haloperidol produced significant reductions in FR5 performance and a shift from lever pressing to chow intake in rats tested on FR5/chow feeding choice, with no evidence of tolerance over the 4-week infusion period. Behavior returned to baseline during the vehicle-infusion washout period. Istradefylline significantly reversed the effects of haloperidol, increasing lever pressing and decreasing chow intake in haloperidol-treated rats.
Conclusions
These studies provide an important behavioral characterization of the effects of chronically infused haloperidol, and demonstrate that A2A antagonism reverses the effects of chronic haloperidol. This research could contribute to the understanding and treatment of motivational dysfunctions seen in schizophrenia, Parkinson’s disease, and other disorders involving dopamine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abe C, Tashiro T, Tanaka K, Ogihara R, Morita H (2009) A novel type of implantable and programmable infusion pump for small laboratory animals. J Pharmacol Toxicol Methods 59(1):7–12. https://doi.org/10.1016/j.vascn.2008.09.002
Abe K, Fujita M, Yoshikawa H (2016) Effectiveness of Istradefylline for Fatigue and Quality of Life in Parkinson’s Disease Patients’ and of Their Caregivers’. Adv Parkinson’s Dis 5:24–28
Aberman JE, Salamone JD (1999) Nucleus accumbens dopamine depletions make rats more sensitive to high ratio requirements but do not impair primary food reinforcement. Neuroscience 92(2):545–552. https://doi.org/10.1016/s0306-4522(99)00004-4
Artaloytia JF, Arango C, Lahti A et al (2006) Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry 163(3):488–493. https://doi.org/10.1176/appi.ajp.163.3.488
Bailey MR, Chun E, Schipani E, Balsam PD, Simpson EH (2020) Dissociating the effects of dopamine D2 receptors on effort-based versus value-based decision making using a novel behavioral approach. Behav Neurosci 134(2):101–118. https://doi.org/10.1037/bne0000361
Barch DM, Gold JM, Kring AM (2017) Paradigms for assessing hedonic processing and motivation in humans: relevance to understanding negative symptoms in psychopathology. Schizophr Bull 43(4):701–705
Barnes SA, Der-Avakian A, Markou A (2014) Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 24(5):744–758. https://doi.org/10.1016/j.euroneuro.2013.10.001
Bitter I, Fehér L, Tényi T, Czobor P (2015) Treatment adherence and insight in schizophrenia. Psychiatr Hung 30(1):18–26
Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V (2014) The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 4(5):198–219. https://doi.org/10.1177/2045125314540297
Caligiuri MP, Ellwanger J (2000) Motor and cognitive aspects of motor retardation in depression. J Affect Disord 57:83–93
Canonica T, Zalachoras I (2022) Motivational disturbances in rodent models of neuropsychiatric disorders. Front Behav Neurosci 16:940672. https://doi.org/10.3389/fnbeh.2022.940672
Chouinard G, Jones B, Remington G et al (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients [published correction appears in J Clin Psychopharmacol 1993 Apr; 13(2):149]. J Clin Psychopharmacol 3(1):25–40
Cousins MS, Salamone JD (1994) Nucleus accumbens dopamine depletions in rats affect relative response allocation in a novel cost/benefit procedure. Pharmacol Biochem Behav 49(1):85–91. https://doi.org/10.1016/0091-3057(94)90460-x
Culbreth AJ, Moran EK, Kandala S, Westbrook A, Barch DM (2020) Effort, avolition and motivational experience in schizophrenia: Analysis of behavioral and neuroimaging data with relationships to daily motivational experience. Clin Psychol Sci 8(3):555–568. https://doi.org/10.1177/2167702620901558
Demyttenaere K, De Fruyt J, Stahl SM (2005) The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol 8:93–105. https://doi.org/10.1017/S1461145704004729
Eklund K, Forsman A (1991) Minimal effective dose and relapse - double-blind trial: haloperidol decanoate vs. placebo. Clin Neuropharmacol 14(2):7–15 (CSzG: Ref 747)
Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J (2008) Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 30(12):2378–2386. https://doi.org/10.1016/j.clinthera.2008.12.020
Errante EL, Chakkalamuri M, Akinbo OI, Yohn SE, Salamone JD, Matuszewich L (2021) Sex differences in effort-related decision-making: role of dopamine D2 receptor antagonism. Psychopharmacology 238(6):1609–1619. https://doi.org/10.1007/s00213-021-05795-x
Essali A, Turkmani K, Aboudamaah S, AbouDamaah A, Diaa Aldeen MR, Marwa ME, AlMounayer N (2019) Haloperidol discontinuation for people with schizophrenia. Cochrane Database Syst Rev 4(4):CD011408. https://doi.org/10.1002/14651858.CD011408.pub2
Farrar AM, Segovia KN, Randall PA, Nunes EJ, Collins LE, Stopper CM, Port RG, Hockemeyer J, Müller CE, Correa M, Salamone JD (2010) Nucleus accumbens and effort-related functions: behavioral and neural markers of the interactions between adenosine A2A and dopamine D2 receptors. Neuroscience 166:1056–1067
Fava M, Ball S, Nelson JC, Sparks J, Konechnik T, Classi P et al (2014) Clinical relevance of fatigue as a residual symptom in major depressive disorder. Depress Anxiety 31:250–257
Fervaha G, Foussias G, Takeuchi H, Agid O, Remington G (2015) Measuring motivation in people with schizophrenia. Schizophr Res 169(1–3):423–426. https://doi.org/10.1016/j.schres.2015.09.012
Friedman JH, Brown RG, Comella C, Garber CE et al (2007) Fatigue in Parkinson’s Disease: A review. Mov Disord 22:297–308
Gao J, Li M (2013) Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism. Behav Brain Res 257:286–294. https://doi.org/10.1016/j.bbr.2013.09.050
Gold JM, Strauss GP, Waltz JA, Robinson BM, Brown JK, Frank MJ (2013) Negative symptoms of schizophrenia are associated with abnormal effort-cost computations. Biol Psychiatry 74(2):130–136. https://doi.org/10.1016/j.biopsych.2012.12.022
Harvey RC, James AC, Shields GE (2016) A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. CNS Drugs 30(1):27–39. https://doi.org/10.1007/s40263-015-0308-1
Kelley ME, van Kammen DP, Allen DN (1999) Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am J Psychiat 156 (3), 406–411. https://doi-org.ezproxy.lib.uconn.edu/10.1176
Kring AM, Barch DM (2014) The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs. Eur Neuropsychopharmacol 24(5):725–736. https://doi.org/10.1016/j.euroneuro.2013.06.007
Kurachi M, Shibata R, Murata M, Tanii Y (1995) Parallel development of dopamine metabolism tolerance in the rat prefrontal cortex, caudate-putamen, and amygdala following haloperidol decanoate administration. Biol Psychiat 37:487–490
Li M (2016) Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms. J Psychopharmacol 30:749–770. https://doi.org/10.1177/0269881116654697
Mai B, Sommer S, Hauber W (2012) Motivational states influence effort-based decision making in rats: the role of dopamine in the nucleus accumbens. Cogn Affect Behav Neurosci 12(1):74–84. https://doi.org/10.3758/s13415-011-0068-4
Mas S, Gassó P, Fernández de Bobadilla R, Arnaiz JA, Bernardo M, Lafuente A (2013) Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. Hum Psychopharmacol. 28(6):586–93. https://doi.org/10.1002/hup.2350
McEvoy JP, Byerly M, Hamer RM et al (2014) Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 311(19):1978–1987. https://doi.org/10.1001/jama.2014.4310
Mott AM, Nunes EJ, Collins LE, Port RG, Sink KS, Hockemeyer J, Müller CE, Salamone JD (2009) The adenosine A2A MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a t-maze cost/benefit procedure. Psychopharmacology 204:103–112
Nagayama H, Kano O, Murakami H, Ono K, Hamada M, Toda T, Sengoku R, Shimo Y, Hattori N (2019) Effect of istradefylline on mood disorders in Parkinson’s disease. J Neurol Sci 396:78–83. https://doi.org/10.1016/j.jns.2018.11.005
Nomoto M, Nagai M, Nishikawa N (2014) Clinical nonmotor aspect of A2A antagonist in PD treatment. Int Rev Neurobiol 119:191–194. https://doi.org/10.1016/B978-0-12-801022-8.00009-X
Nunes EJ, Randall PA, Santerre JL, Given AB, Sager TN, Correa M, Salamone JD (2010) Differential effects of selective adenosine antagonists on the effort-related impairments induced by dopamine D1 and D2 antagonism. Neuroscience 170(1):268–280. https://doi.org/10.1016/j.neuroscience.2010.05.068
Nunes EJ, Randall PA, Hart EE, Freeland C, Yohn SE, Baqi Y, Müller CE, López-Cruz L, Correa M, Salamone JD (2013) Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression. J Neurosci 33(49):19120–19130. https://doi.org/10.1523/JNEUROSCI.2730-13.2013
Pardo M, Lopez-Cruz L, Valverde O, Ledent C, Baqi Y, Müller CE, Salamone JD, Correa M (2012) Adenosine A2A receptor antagonism and genetic deletion attenuate the effects of dopamine D2 antagonism on effort-based decision making in mice. Neuropharmacology 62(5–6):2068–2077. https://doi.org/10.1016/j.neuropharm.2011.12.033
Pardo M, Paul NE, Collins-Praino LE, Salamone JD, Correa M (2020) The non-selective adenosine antagonist theophylline reverses the effects of dopamine antagonism on tremor, motor activity and effort-based decision-making. Pharmacol Biochem Behav 198:173035. https://doi.org/10.1016/j.pbb.2020.173035
Phan SV (2016) Medication adherence in patients with schizophrenia. Int J Psychiatry Med 51(2):211–219. https://doi.org/10.1177/0091217416636601
Randall PA, Pardo M, Nunes EJ, López Cruz L, Vemuri VK, Makriyannis A et al (2012) Dopaminergic modulation of effort-related choice behavior as assessed by a progressive ratio chow feeding choice task: pharmacological studies and the role of individual differences. Plos One 7(10):e47934. https://doi.org/10.1371/journal.pone.0047934
Randall PA, Lee CA, Nunes EJ, Yohn SE, Nowak V, Khan B, Shah P, Pandit S, Vemuri VK, Makriyannis A, Baqi Y, Müller CE, Correa M, Salamone JD (2014) The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs. Plos One 9(6):e99320
Reddy LF, Horan WP, Barch DM, Buchanan RW, Dunayevich E, Gold JM, Lyons N, Marder SR, Treadway MT, Wynn JK, Young JW, Green MF (2015) Effort-based decision-making paradigms for clinical trials in schizophrenia: Part 1—Psychometric characteristics of 5 paradigms. Schizophr Bull 41(5):1045–1054. https://doi.org/10.1093/schbul/sbv089
Remington G, Kapur S (2010) Antipsychotic dosing: how much but also how often? Schiz Bull 36(5):900–903. https://doi.org/10.1093/schbul/sbq083
Rotolo RA, Dragacevic V, Kalaba P, Urban K, Zehl M, Roller A, Wackerlig J, Langer T, Pistis M, De Luca MA, Caria F, Schwartz R, Presby RE, Yang JH, Samels S, Correa M, Lubec G, Salamone JD (2019) The novel atypical dopamine uptake inhibitor (S)-CE-123 partially reverses the effort-related effects of the dopamine depleting agent tetrabenazine and increases progressive ratio responding. Front Pharm 10:682. https://doi.org/10.3389/fphar.2019.00682
Rotolo RA, Kalaba P, Dragacevic V, Presby RE, Neri J, Robertson E, Yang JH, Correa M, Bakulev V, Volkova NN, Pifl C, Lubec G, Salamone JD (2020) Behavioral and dopamine transporter binding properties of the modafinil analog (S, S)-CE-158: reversal of the motivational effects of tetrabenazine and enhancement of progressive ratio responding. Psychopharmacology 237(11):3459–3470. https://doi.org/10.1007/s00213-020-05625-6
Rotolo RA, Presby RE, Tracey O, Asar S, Yang J-H, Correa M, Murray F, Salamone JD (2021) The Novel Atypical Dopamine Transport Inhibitor CT-005404 Reverses the Effort-Related Motivational Effects of Tetrabenazine and Interleukin-1β and Increases Progressive Ratio Responding. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2020.108325
Salamone JD, Correa M (2002) Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res 137:3–25
Salamone JD, Correa M (2012) The mysterious motivational functions of mesolimbic dopamine. Neuron 76:470–485
Salamone JD, Correa M (2022) Critical review of RDoC approaches to the study of motivation with animal models: effort valuation/willingness to work. Emerg Top Life Sci. https://doi.org/10.1042/ETLS20220008
Salamone JD, Steinpreis RE, McCullough LD, Smith P, Grebel D, Mahan K (1991) Haloperidol and nucleus accumbens dopamine depletion suppress lever pressing for food but increase free food consumption in a novel food choice procedure. Psychopharmacology 104(4):515–521. https://doi.org/10.1007/BF02245659
Salamone JD, Cousins MS, Bucher S (1994) Anhedonia or anergia? Effects of haloperidol and nucleus accumbens dopamine depletion on instrumental response selection in a T-maze cost/benefit procedure. Behav Brain Res 65:221–229
Salamone JD, Cousins MS, Snyder BJ (1997) Behavioral functions of nucleus accumbens DA: empirical and conceptual problems with the anhedonia hypothesis. Neurosci Biobehav Rev 21:341–359
Salamone JD, Correa M, Mingote SM, Weber SM, Farrar AM (2006) Nucleus accumbens dopamine and the forebrain circuitry involved in behavioral activation and effort-related decision making: implications for understanding anergia and psychomotor slowing in depression. Curr Psychiatry Rev 2:267–280
Salamone JD, Correa M, Farrar A, Mingote SM (2007) Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits. Psychopharmacology 191:461–482
Salamone JD, Correa M, Farrar AM, Nunes EJ, Collins LE (2010) Role of dopamine-adenosine interactions in the brain circuitry regulating effort-related decision making: insights into pathological aspects of motivation. Future Neurol 5:377–392
Salamone JD, Yohn SE, Lopez-Cruz L, San Miguel N, Correa M (2016) Activational aspects of motivation: neural mechanisms and implications for psychopathology. Brain 139:1325–1347
Salamone JD, Correa M, Ferrigno S, Yang JH, Rotolo RA, Presby RE (2018) The Psychopharmacology of Effort-Related Decision Making: Dopamine, Adenosine, and Insights into the Neurochemistry of Motivation. Pharmacol Rev 70(4):747–762
Salamone JD, Ecevitoglu A, Carratala-Ros C, Presby RE, Edelstein GA, Fleeher R, Rotolo RA, Meka N, Srinath S, Masthay JC, Correa M (2022) Complexities and paradoxes in understanding the role of dopamine in incentive motivation and instrumental action: Exertion of effort vs. anhedonia. Brain Res Bull 182:57–66. https://doi.org/10.1016/j.brainresbull.2022.01.019
Santerre JL, Nunes EJ, Kovner R et al (2012) The novel adenosine A(2A) antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions. Pharmacol Biochem Behav 102(4):477–487. https://doi.org/10.1016/j.pbb.2012.06.009
Schweimer J, Saft S, Hauber W (2005) Involvement of catecholamine neurotransmission in the rat anterior cingulate in effort-related decision making. Behav Neurosci 119(6):1687–1692. https://doi.org/10.1037/0735-7044.119.6.1687
Sebel LE, Graves SM, Chan CS, Surmeier DJ (2017) Haloperidol Selectively Remodels Striatal Indirect Pathway Circuits. Neuropsychopharmacology 42(4):963–973. https://doi.org/10.1038/npp.2016.173
Sink KS, Vemuri VK, Olszewska T, Makriyannis A, Salamone JD (2008) Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior. Psychopharmacology 196(4):565–574. https://doi.org/10.1007/s00213-007-0988-4
Stahl SM (2002) The psychopharmacology of energy and fatigue. J Clin Psychiat 63:7–8
Strauss GP, Waltz JA, Gold JM (2014) A review of reward processing and motivational impairment in schizophrenia. Schizophr Bull 40(Suppl 2):S107-166. https://doi.org/10.1093/schbul/sbt197
Strauss GP, Bartolomeo LA, Harvey PD (2021) Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development. NPJ Schizophr 7(1):16. https://doi.org/10.1038/s41537-021-00145-4
Tan T, Watts SW, Davis RP (2011) Drug Delivery: Enabling Technology for Drug Discovery and Development. Iprecio Micro Infusion Pump: Programmable, Refillable, and Implantable. Front Pharmacol 2:44. https://doi.org/10.3389/fphar.2011.00044
Treadway MT, Salamone JD (2022) Vigor, Effort-Related Aspects of Motivation and Anhedonia. Curr Top Behav Neurosci 58:325–353. https://doi.org/10.1007/7854_2022_355
Treadway MT, Zald DH (2011) Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev 35:537–555
Treadway MT, Bossaller NA, Shelton RC, Zald DH (2012) Effort-based decision-making in major depressive disorder: a translational model of motivational anhedonia. J Abnorm Psychol 121(3):553–558
Treadway MT, Peterman JS, Zald DH, Park S (2015) Impaired effort allocation in patients with schizophrenia. Schizophr Res 161(2–3):382–385. https://doi.org/10.1016/j.schres.2014.11.024
Trevitt J, Atherton A, Aberman J, Salamone JD (1998) Effects of subchronic administration of clozapine, thioridazine and haloperidol on tests related to extrapyramidal motor function in the rat. Psychopharmacology 137(1):61–66. https://doi.org/10.1007/s002130050593
Worden LT, Shahriari M, Farrar AM, Sink KS, Hockemeyer J, Müller CE, Salamone JD (2009) The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists. Psychopharmacology 203:489–499
Xiao J, Mi W, Li L, Shi Y, Zhang H (2015) High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People’s Republic of China. Neuropsychiatr Dis Treat 11:1161–7
Yang JH, Presby RE, Jarvie AA, Rotolo RA, Fitch RH, Correa M, Salamone JD (2020) Pharmacological studies of effort-related decision making using mouse touchscreen procedures: effects of dopamine antagonism do not resemble reinforcer devaluation by removal of food restriction. Psychopharmacology 237:33–43. https://doi.org/10.1007/s00213-019-05343-8
Yohn SE, Thompson C, Randall PA, Lee CA, Müller CE, Baqi Y, Correa M, Salamone JD (2015) The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion. Psychopharmacology 232(7):1313–1323. https://doi.org/10.1007/s00213-014-3766-0
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interests
This research was supported by a grant from Lundbeck. JS has received grants from, and done consulting work for Shire, Prexa, Chronos, Blackthorn, Acadia, Otsuka, and Lundbeck. On behalf of all authors, the corresponding author states that there is no conflict of interest.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Rotolo, R.A., Ecevitoglu, A., Presby, R.E. et al. Effort-related effects of chronic administration of the DA D2 receptor antagonist haloperidol via subcutaneous programmable minipumps: Reversal by co-administration of the adenosine A2A antagonist istradefylline. Psychopharmacology 240, 2173–2185 (2023). https://doi.org/10.1007/s00213-023-06439-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-023-06439-y